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Conversion from calcineurin inhibitors to sirolimus of recipients with
chronic kidney graft disease grade III for a period 2003–2011
Konverzija sa kalcineurinskih inhibitora na sirolimus kod primalaca sa
hroniþnom  insuficijencijom bubrežnog grafta treüeg stepena
u periodu 2003–2011.
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Abstract
Background/Aim.  Tremendous breakthrough in solid
organ transplantation was made with the introduction of
calcineurin inhibitors (CNI). At the same time, they are
potentially nephrotoxic drugs with influence on onset and
progression of renal graft failure. The aim of this study
was to evaluate the outcome of a conversion from CNI-
based immunosuppressive protocol to sirolimus (SRL) in
recipients with graft in chronic kidney disease (CKD)
grade III and proteinuria below 500 mg/day. Methods. In
the period 2003–2011 24 patients (6 famale and 18 male),
mean age 41  ±  12.2 years, on triple immunosuppressive
therapy: steroids, antiproliferative drug [mycophenolate
mofetil (MMF) or azathiopirine (AZA)] and CNI were
switched from CNI to SRL and followe-up for 76 ± 13
months. Nine patients (the group I) had early postrans-
plant conversion after 4 ± 3  months and 15 patients (the
group II) late conversion after 46 ± 29 months. During
the regular outpatient controls we followed graft function
through the serum creatinine and glomerular filtration rate
(GFR), proteinuria, lipidemia and side effects. Results.
Thirty days after conversion, in all the patients GFR, pro-
teinuria and lipidemia were insignificantly increased. In the
first two post-conversion months all the patients had at
least one urinary or respiratory infection, and 10 patients
reactivated cytomegalovirus (CMV) infection or disease,
and they were successfully treated with standard therapy.
After 21 ± 11 months 15 patients from both groups dis-
continued SRL therapy due to reconversion to CNI (10
patients) and double immunosuppressive therapy (3 pa-
tients), return to hemodialysis (1 patient) and death (1 pa-
tient).  Nine patients were still on SRL therapy. By the end
of the follow-up they significantly improved GFR (from
53.2  ±  12.7 to 69  ±  15 mL/min), while the increase in
proteinuria  (from  265 ± 239  to  530.6 ± 416.7  mg/day)
and lipidemia (cholesterol from 4.71 ± 0.98 to 5.61 ± 1.6
mmol/L and triglycerides from 2.04 ± 1.18 to 2.1 ± 0.72
mmol/L) were not significant. They were stable during the
whole follow-up period. Ten patients were reconverted
from SRL to CNI due to the abrupt increase of protein-
uria (from 298  ±  232 to 1639  ±  1641/mg day in 7 pa-
tients), rapid growth of multiple ovarian cysts (2 patients)
and operative treatment of  persisted hematoma (1 pa-
tient). Thirty days after reconversion  they were stable with
an insignificant decrease in GFR (from 56.10  ±  28.09 to
47  ±  21 mL/min) and significantly improved proteinuria
(from 1639 ± 1641 to 529 ± 688 mg/day). By the end of
the follow-up these patients showed nonsignificant increase
in the serum creatinine (from 172  ±  88 to 202  ±  91
mmol/L), decrease in GFR (from 56.10 ± 28.09 to 47 ± 21
mL/day) and increased proteinuria (from 528.9  ±  688 to
850 ± 1083 mg/min). Conclusion. In this small descriptive
study, conversion from CNI to SRL was followed by an in-
creased incidence of infections and consecutive 25–50%
dose reduction in the second antiproliferative agent (AZA,
MMF), with a possible influence on the development of
glomerulopathy in some patients, which was the major rea-
son for discontinuation of SRL therapy in the 7 (29%) pa-
tients. Nine (37.5%) of the patients experienced the great-
est benefit of CIN to SRL conversion without serious
post-conversion complications.
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Apstrakt
Uvod/Cilj. Znaÿajan prodor u transplantaciji solidnih or-
gana postignut je uvoĀenjem kalcineurinskih inhibitora
(KNI). Istovremeno, njihovi potencijalno nefrotoksiÿni efe-
kti mogu da doprinesu nastanku i progresiji insuficijencije
bubrežnog grafta. Cilj ispitivanja bio je da se utvrdi ishod
konverzije sa imunosupresivnih protokola baziranih na KNI
na sirolimus (SRL) kod primalaca sa treýim stepenom hro-
niÿne bubrežne slabosti grafta i proteinurijom manjom od
500 mg/dan. Metode. U periodu od 2003. do 2011. 24 bo-
lesnika (6 žena i 18 muškaraca), proseÿne starosti 41 ± 12,2
godine, na trostrukoj imunosupresivnoj terapiji: steroidi,
antiproliferativni lek [mekofenolat mofetil (MMF)/ azatiop-
rin (AZA)] i KNI prevedeno je sa KNI na SRL i praýeno
76 ± 13 meseci. Devet bolesnika (I grupa) prevedeno je ra-
no, tokom prve postransplantacione godine (4 ± 3 meseca) i
15 kasno, nakon prve godine (46 ± 29 meseci). Tokom re-
dovnih ambulantnih kontrola pratili smo funkciju grafta
praýenjem vrednosti serumskog kreatinina,  jaÿine glomerul-
ske filtarcije (JGF), proteinurije i lipidemije. Rezultati. Tri-
desetog dana nakon konverzije kod svih bolesnika vrednosti
JGF, proteinurije i lipidemije bile su neznato poveýane. To-
kom prva dva meseca svi bolesnici imali su makar jednu
urinarnu ili respiratornu infekciju, a kod 10 bolesnika se rea-
ktivirala citomegalovirusna infekcija/bolest, Bolesnici su us-
pešno izleÿeni standardnom terapijom. U preriodu od 21
± 11 meseci kod 15 bolesnika iz obe grupe obustavljena je
terapija SRL zbog: rekonverzije na KNI (10 bolesnika) ili
dvostruke imunosupresivne terapije (3 bolesnika), vraýanja
na hemodijalizu (1 bolesnik) i smrti (1 bolesnik). Devet bo-
lesnika bilo je i dalje na terapiji SRL. Do kraja praýenja oni
su znatno popravili JGF (sa 53,2  ±  12,7 na 69  ±  15
mL/min), a neznatno poveýali proteinuriju (sa 265 ± 239 na
530,6  ±  416,7 mg/dan) i lipidemiju (holesterol sa
4,71  ±  0,98 na 5,61  ±  1,6 mmol/L i trigliceride sa
2,04 ± 1,18 na 2,1 ± 0,72 mmol/L). Svi su bili stabilni to-
kom praýenja. Deset bolesnika vraýeno je na KNI zbog na-
glog poveýanja proteinurije, sa 298 ± 232 na 1639 ± 1641
mg/dan (7 bolesnika), brzog rasta multiplih ovarijalnih cista
(2 bolesnika) i operativnog leÿenja perzistentnog hematoma
(1 bolesnik). Od rekonverzije do kraja praýenja bili su sta-
bilni, ali sa neznatnim sniženjem JGF (sa 56,10 ± 28,09 na
47  ±  21 mL/min) i znaÿajno nižom proteinurijom (sa
1639 ± 1641 na 529 ± 688 mg/dan). Do kraja praýenja kod
njih se neznatno poveýala vrednost serumskog kreatinina (sa
172 ± 88 na 202 ± 91 mmol/L), smanjila vrednost JGF (sa
56,10 ± 28,09 na 47 ± 21 mL/min) i poveýala proteinurija (sa
528,9 ± 688  na  850 ± 1083  mg/dan).  Zakljuÿak. U ovom
malom deskriptivnom ispitivanju prevoĀenje sa KNI na SRL
bilo je praýeno veýom incidencijom infektivnih komplikacija,
što je uslovilo sniženje doze drugog antiproliferativnog leka
(AZA ili MMF) za 25–50% i moguýe imalo uticaj na pojavu
glomerulopatije, koja je bila razlog za prekid terapije sirolimu-
som kod sedam (29%) bolesnika. Najveýu korist od konver-
zije sa CNI na SRL imalo je devet (37,5%) bolesnika koji nisu
ispoljili znaÿajne komplikacije nakon konverzije.
Kljuÿne reÿi:
transplantacija bubrega; graft, preživljavanje; bubreg,
hroniÿna insuficijencija; kalcineurin; sirolimus; bolest,
progresija.
Introduction
Possible beneficial effects of early postransplant conver-
sion from calcineurin inhibitors (CNI) to sirolimus (SRL) in
patients with normal renal graft function and proteinuria have
been well documented in recently published papers 
1–4. There
are only a few papers with a small number of patients dealing
with conversion from CNI to SRL-based protocol in patients
with graft chronic kidney disease 
5–11. The main idea of this
conversion was to prolong the duration of graft chronic kidney
disease (CKD) and postpone the dialysis. It is well-known that
patients who are on these less toxic protocols are at a higher
risk for subclinical, acute and chronic rejection if, through
SRL concentration was lower than 10–15 ng/mL in the first 6
months 
11. In the same time the risk for malignancies 
12–14 and
cardiovascular events should be decreased 
15, 16.
The aim of the study was to investigate the outcome of
conversion from immunosuppressive protocol based on CNI to
SRL, measuring glomerular filtration rate (GFR) estimated by
the Cockcroft-Gault equation, proteinuria, lipidemia and resisti-
ve index of interlobar arteries, as well as side effects in patients
with graft CKD grade III and proteinuria below 500 mg/day.
Methods
From March 2003 to December 2011, 24 patients (6
females and 18 males) were switched from immunosuppres-
sive protocols based on CNI (15 cyclosporine A and 9 tacro-
limus) with steroids and antiproliferative agent [azathioprine
(AZA) or mycophenolate mofetil (MMP)] to SRI and
prospectively followed 76 ± 13 months.
Before transplantation, all the patients had slowly pro-
gressive chronic kidney disease that lasted more than 10
years: chronic glomerulonephritis (21 patients), endemic
nephropathy (1 patient) and congenital anomalies (2 pati-
ents). The patients with glomerulonephritis presented mostly
with daily proteinuria below 1 or 2 gr, some of them with
intermittent or persistent microhematuria and mild, easily
controlled hypertension (with ACE inhibitor and/or diure-
tics). Only four patients were histologically verified: three
with IgA nephropathy and one with rapidly progressive glo-
merulonephritis (anti-glomerular basement membrane positi-
ve with isolated renal disease).
Eighteen patients received a graft from living related
donors, and six from deceased donors. HLA matching was
50  ±  12,5%, panel reactive antibody (PRA) was zero and
pretransplant lymphocytotoxic cross match was negative. All
the patients had increased blood pressure, kept in target ran-
ge (120–130/70–80 mmHg) with a low dose of beta blocker
in combination with an ACE inhibitor or a calcium channel
blocker.
Before conversion from CNI to SRL all the patients had
graft CKD grade III estimated by the Cockcroft-Gault
equation and daily proteinuria below 500 mg. Graft functionStrana 850 VOJNOSANITETSKI PREGLED Volumen 70, Broj 9
Ignjatoviý Lj, et al. Vojnosanit Pregl 2013; 70(9): 848–853.
in these patients was suboptimal initially, due to older donor
age and nephroangiosclerosis, or as a consequence of an is-
chemic-reperfusion injury. Although most of these patients,
as expected, had histology verification for mild or moderate
tubulointerstitial fibrosis, the aim of this study was to deter-
mine clinical parameters, particularly GFR and proteinuria,
as markers of efficient conversion from CNI to SRL.
Two groups of patients were formed based on timing of
conversion: the early and the late. The early converted group
had 9 patients converted before the end of the first postrans-
plant year (mean 4 ± 3 months post-transplant), with protei-
nuria below 150 mg/day in two patients and from 150–500
mg/day (379 ± 232 mg/day) in seven patients. The late con-
verted group included 15 patients that were switched after
the first postransplant year (mean 46  ±  26 months), with
proteinuria below 150 mg/day in eight patients and 150–500
mg/day in remaining seven patients (mean 215  ±  207
mg/day).
Before switching to SRL, basic clinical examination
was performed. It consisted of physical examination and
evaluation of morphology and hemodynamics of renal graft
by color Doppler sonography in the level of interlobar arteri-
es. Basic laboratory analysis, blood cell count and standard
biochemical parameters were checked (serum creatinine,
cholesterol and triglycerides). Graft function was evaluated
by serum creatinine and GFR estimated by the Cockcroft –
Gault equation. Proteinuria was measured in daily urine
samples using the biuret method.
Conversion from CNI to SRL was abrupt. After a night
dose of CNI, next morning the first dose of SRL was intro-
duced. First C0 SRL concentration was monitored the third
day with target levels of 7–10 ng/mL from 6th to 12th post-
transplant months and 5–10 ng/mL after first post transplant
year. When SRL reached the target range, the doses of antip-
roliferative drugs were decreased by 25–50% (MMF from 2
g to maximum 1.5 g, and AZA from 125 or 150 mg to
maximum 100 mg). Steroids were kept at maintenance doses
(5–10 mg daily).
After conversion, check-ups were on day 3, 6 and 30,
then switched to weekly between 3 to 6 months, bi-weekly
between 6 to 9 months, monthly between 9 to 12 months and
every three months after one year. Follow-up on each visit
included serum creatinine, GFR calculated using the Coc-
kcroft-Gault equation and side effects (worsening of
hypertension, lipidemia and proteinuria, new episodes of
acute rejection, infections, acute cardiovascular incidents,
patients and graft survival and new onset of malignancies).
Worsening of proteinuria above 1 g/day was a marker of
glomerulopathy development in the course of graft CKD.
All blood analyses were done in our central laboratory
using standard procedures. Hematologic analyses were per-
formed on autoanalyzer (Bayer). Creatinine concentration
was measured colorimetrically with alkaline picrate (Dimen-
sion RXL Dade Behring).
The Cockcroft–Gault equation allows creatinine clea-
rance to be estimated from the serum creatinine:
CCr (mL/min) =
72   [mg/dL]   CrS
(kg) t  body weigh lean  ) 140 (
u +
u  age
u 0.85 (if female)
SRL C0 concentration was measured with Imx Siroli-
mus Assay based on MEIA (micro particular enzyme
immunoassay) technology (Abbot). Reactivation of
cytomegalovirus infection was detected with PCR method on
Amplicor Hoffman La Roche with positive test above 400
copies/L.
For statistical analysis we used t-test in Excel on sta-
ndard personal computers. The results of analysis were pre-
sented in tables as mean value ± 1 SD (standard deviation)
and probability was considered significant if p < 0.05.
Results
Initially, all the patients showed a benefit of conversion
from CNI to SRL. One month after conversion, the patients
from both groups improved graft function and increased lipi-
demia and proteinuria. Graft hemodynamics, expressed as
measured resistive index in interlobar arteries, although
significantly increased in the early group, stayed within the
referent range (Tables 1 and 2).
During the 8-year follow-up, 15 patients (out of 24) di-
scontinued sirolimus therapy for different reasons (Table 3).
Nine patients that remained on sirolimus therapy,
followed for 65 ± 20 months, significantly improved hemo-
globin and graft function. Proteinuria and lipidemia increa-
sed insignificantly and hemodynamic parameters of renal
allograft were unchanged (Table 4).
Ten patients were reconverted to CNI after 21 ±  11
months. Initially, upon conversion they insignificantly im-
Table 1
The results of early conversion from calcincurin inhibitors (CNI)
to sirolimus (SRL) in 9 patients
Parameters CNI
(ʉ ± SD)
SRL (30th day)
(ʉ ± SD) p
Creatinine S (μmol/L) 204 ± 74 166 ± 74 ns
GFR (mL/min) 48.9 ± 16 65.6 ± 23.5 ns
Proteinuria 24 h (mg) 379 ± 22 979 ± 1956. ns
Cholesterol (mmol/L) 4.8 ± 1.5 7.63 ± 0.84 0.001
Triglycerides (mmol/L) 2.63 ± 1.1 4.8 ± 1.74 ns
RI ILA 0.63 ± 0.05 0.68 ± 0.03 0.038
S – serum; GFR – glomerular filtration rate; RI ILA – resistive index in interlobar arteries;
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proved graft function, but later showed a considerable incre-
ase in proteinuria, lipidemia and worsened hemodynamic pa-
rameters in the level of kidney interlobar arteries. They were
reconverted to CNI due to development of glomerulopathy,
which presented with abrupt onset and progressive increase
in proteinuria, mostly in subnephrotic range (7 patients),
newly formed multiple ovarian cysts with consecutive serious
lower extremity edema (2 patients) and an operative treatment
(1 patient). The result of reconversion was a nonsignificant
decrease in proteinuria and worsening of renal function, lipi-
demia and resistive index without hemodynamic consequences
(Table 5). By the end of the total follow-up, 76 ± 13 months,
these patients were still in renal failure grade III, with slowly
progressive nonsignificant increase in serum creatinine, pro-
teinuria and decrease in glomerular filtration rate.
Early after the conversion two of the patients developed
serious crural edema and multiple ovarian cysts with oligo-
menorrhea. After reconversion to CNI they lost edema and
ovarian cysts and returned to a regular period.
Initially, most of our patients had low C0 SRL con-
centration (5–7 ng/mL) and showed early infective compli-
cations in spite of dose correction of the second anti-
proliferative agent. All the converted patients had acute
pyelonephritis caused by E. coli or Enterobacter, and two of
them had pneumonia caused by Hemophillus influence. Ten
patients had symptomatic reactivation of cytomegalovirus
(CMV) infection, successfully treated with ganciclovir or
valganciclovir. Three of the patients with recurrent bacterial
or viral infections stopped SRL therapy, and by the end of
the follow-up had double immunosuppressive therapy with
steroid and a second antiproliferative agent (AZA or MMF).
In these patients GFR and serum creatinine remained in the
same range as at the time of SRL discontinution.
One of the patients during this period progressed to
end-stage renal failure and started dialysis. In the meantime
he had a second transplantation.
One of the patients with apparently inadequate compli-
ance and blood pressure control died after acute massive in-
tracranial bleeding.
No new onset of malignancies was noticed in any of the
followed patients.
In all the followed patients antihypertensive therapy
was unchanged, but the dose of hypolipemic agents was inc-
reased.
Table 2
The results of late conversion from calcineurin inhibitors (CNI)
to sirolimus (SRL) in 15 patients
Parameters CNI
(ʉ ± SD)
SRL (30th day)
(ʉ ± SD) p
Creatinine S (μmol/L) 202 ± 45 167 ± 35 ns
GFR (mL/min) 52.4 ± 11.4 61.8 ± 19 ns
Proteinuria 24 h (mg) 215 ± 207 1051 ± 1920 ns
Cholesterol (mmol/L) 6.25 ± 4.2 5.63 ± 3.12 ns
Triglycerides (mmol/L) 2.24 ± 1.32 3.18 ± 1.57 ns
RI ILA 0.68 ± 0.06 0.68 ± 0.05 ns
S – serum; GFR – glomerular filtration rate; RI ILA – resistive index in interlobar
arteries; ns – non significant.
Table 3
The outcome of conversion from calcineurin inhibitors (CNI)
to sirolimus (SRL)
Group SRL reCNI ST + AP Hd Death
I3 4 1 0 1
II 6 6 2 1 0
Total 9 10 3 1 1
The group I – converted from CIN to SRL before the end of the first posttransplant
years; the group II – converted from CIN to SRL after the first post-transplant
years; reCNI – reconversion to calcineurin inhibitors; ST – steroids; AP – antipro-
liferative agent; Hd-hemodialysis.
Table 4
The patients with sirolimus (SRL) therapy – initial (start) and final (end) results
Parameters CNI start
(ʉ ± SD)
SRL end
(ʉ ± SD) p
Creatinine S (μmol/L) 203 ± 31 167 ± 28 0.01
GFR (mL/min) 53.2 ± 12.7 69 ± 15 0.014
Proteinuria (mg/day) 265 ± 239 530.6 ± 416.7 0.061
Cholesterol (mmol/L) 4.71 ± 0.98 5.6 ± 1.6 0.116
Triglycerides (mmol/L) 2.04 ± 1.18 2.1 ± 0.72 0.45
Hemoglobin (g/L) 124.2 ± 13.1 140.4 ± 14.7 0.013
RI ILA 0.66 ± 0.05 0.66 ± 0.05 0.37
CNI – celcineurine inhibitors; S – Serum; GFR – glomerular filtration rate; RI ILA – resistive index in interlobar
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Discussion
Some authors proposed less toxic immunosuppression
for all renal allograft recipients to minimize the risk for de-
velopment of chronic allograft nephropathy, decrease the in-
cidence of cardiovascular deaths and new onset of malignan-
cies 
12–16. The main idea for patients who already had graft
dysfunction was avoiding calcineurine inhibitors and their
toxic effects on graft hemodynamics, which potentially could
accelerate progression of renal failure 
16. The question re-
mains when the right time is for conversion from CNI to
SRL and who should be converted.
It appears that the timing of conversion is not impor-
tant, while the initial level of renal graft damage is. The
CONVERT trial showed that the best results of conversion
from calcineurin inhibitors to sirolimus showed patients with
GFR above 40 mL/min and urine protein/creatinine ratio less
than 0.11 
1, 2.
The effect of sirolimus on growth factor inhibition re-
sulted in a specific profile of side effects: increased inciden-
ce of postoperative liquid collection, decelerated wound hea-
ling and function recovery of primary non-functioning
grafts 
17, 18. Some authors believe that SRL special profile of
side effects is dose-dependent 
18.
Sirolimus should not be introduced immediately in the
postoperative period and should be avoided in marginal
grafts, patients with long cold ischemia time and high-risk
patients. The best results were seen in patients with low im-
munological risk and without graft dysfunction. Potentially
good candidates may also be patients with stent in renal
artery and newly discovered skin malignancies.
The conversion can be abrupt, but with good C0 SRL
concentration, especially in the first six postransplant months
(10–15 ng/mL) to ensure the minimal risk for subclinical,
acute and chronic rejection. Our patients had lower target
concentrations in the first six months due to serious and re-
current infective complications. None of our patients in the
first post-conversion year had a clinical episode of acute re-
jection, or worsening of chronic graft dysfunction.
Introducing SRL in immunosuppressive protocol since
2003, we converted all those stable, low-risk graft recipi-
ents in grade III renal failure in the first post-transplant
year and later, with normal or slightly increased proteinu-
ria, for which we thought that they could benefit from CNI
withdrawal.
High doses of two antiproliferative immunosuppressive
agents acting in different phases of T and B lymphocyte cell
cycles may potentially result in increase in infectious com-
plication, or facilitate myelotoxic effects or digestive
symptoms 
9.
Ten (42%) of the patients in the period of 21  ±  11
months after the initial conversion, reconverted to CNI after
the increase of 24 h proteinuria above 2 g. The development
of glomerulopathy worsened the course of pre-exisiting
chronic graft dysfunction, but without a significant change in
urinary sediment, serum creatinine or GFR. Histological
examination showed focal and segmental glomerulosclerosis
in all the patients. Thirty days after reconversion to CNI,
proteinuria was below 0.8 g daily and slowly increased to 1.8
g by the end of the follow-up. Graft function was almost the
same as at the beginning of the treatment. Color Doppler
evaluation of kidney hemodynamics through resistive indices
in interlobar arteries of renal graft stayed in the normal range
(below 0.7), which additionally confirmed the stability of
graft function and good potential for future graft survival.
The reason for such increase in proteinuria could be
explained partly by low total dose of immunosuppressive
therapy (low C0 SRL concentration combined with additio-
nal decrease in the dose of the second antiproliferative agent
due to serious infectious complications). Notwithstanding
with these findings, some authors reported development of
glomerulopathy in the patients with high C0 SRL concentra-
tions 
19. An explanation for this could be that it represents the
progression of pre-existing disease, or that it is a
consequence of specific SRL side-effect profile with impact
on podocytopathy 
20.
Almost all the papers about conversion from CNI to
SRL stressed the worsening of lipidemia in spite of the cor-
rection of hypolipemic therapy. Our patients showed insigni-
ficant increase in serum lipids. They were not using
hypolipemic therapy regularly because they could not afford
or refund this expensive therapy. The patients with SRL
therapy, in spite of the persistent dyslipidemia, did not show
deteriorating effect on graft function.
Conclusion
In this small prospective and descriptive study CNI to
SRL conversion was followed by the increased incidence of
infections and consecutive 25–50% dose reduction of the se-
Table 5
The patients converted from calcineurin inhibitors (CNI) to sirolimus (SRL) and reconverted to CNI (reCIN) on day 30, and
at the end of follow-up (after 76 ± 13months)
Parameters CNI start
(ʉ ± SD)
SRL end
(ʉ ± SD)
p
CNI start : SRLend
reCNI, 30th day
(ʉ ± SD)
CNI end
(ʉ ± SD)
p
reCNI:CNI end
CreatinineS (μmol/L) 185 ± 76 167 ± 61 0.28 172 ± 88 202 ± 91
GFR (mL/min) 49.45 ± 13,54 55.82 ± 22.67 0.23 56.10 ± 28.09 47 ± 21
Proteinuria (mg/day) 298 ± 232.13 1639 ± 1641* 0.015 528.9 ± 688* 850 ± 1083 ns* / ns
Cholesterol (mmol/L) 5.6 ± 1.6 7.22 ± 0.95 0.011
Triglycerides (mmol/L) 2.39 ± 0.68 4.37 ± 1.42 0.001
RI ILA 0.66 ± 0.06 0.69 ± 0.04 0.177
* – Compared values at the end of SRL therapy to those 30 days after reconversion to CNI; GFR – glomerular filtration rate;
RI ILA – resistive index in interlobar arteries; ns – non significant.Volumen 70, Broj 9 VOJNOSANITETSKI PREGLED Strana 853
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cond antiproliferative agent (AZA, MMF), with a possible
influence on the development of glomerulopathy in some
patients, which was the major reason for discontinuation of
SRL therapy in 7 (29%) of the patients. Nine (37.5%) of the
patients experienced the greatest benefit of CNI to SRL con-
version without serious post-conversion complications.
Worsened lipidemia could be corrected with regular use
and proper dose of hypolipemic agents and did not influence
GFR in patients on SRL therapy. Patients reconverted to cal-
cineurin inhibitors showed slow and progressive chronic
kidney graft disease.
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